Showing results (341-350 of 363) with videos related to

Sort By:
Pageof 37
Neuroscience|March 31, 2010
Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activationE A Hackler, N E Byun, C K Jones, et al.
Journal of Enzyme Inhibition|January 1, 1996
Comparative effects of selective cyclooxygenase 1 and cyclooxygenase 2 inhibitors on myeloperoxidase and 3 alpha-hydroxysteroid dehydrogenaseN L Rider, D Pinto, M Covington, et al.
Glycoconjugate Journal|October 1, 1996
Colonic mucins in ulcerative colitis: evidence for loss of sulfationA P Corfield, N Myerscough, N Bradfield, et al.
Molecular Immunology|March 23, 2010
Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome-A pedigree revisitedS A Johnson, J M Williams, S Hakobyan, et al.
Prenatal Diagnosis|April 1, 1996
Development of a model system to compare cell separation methods for the isolation of fetal cells from maternal bloodD W Bianchi, K W Klinger, T J Vadnais, et al.
Thin Solid Films|April 3, 2009
Tribo-mechanical properties of thin boron coatings deposited on polished cobalt alloy surfaces for orthopedic applicationsC C Klepper, J M Williams, J J Truhan, et al.
Epidemiology and Infection|November 26, 2011
Epidemiology of a large restaurant-associated outbreak of Shiga toxin-producing Escherichia coli O111:NMK K Bradley, J M Williams, L J Burnsed, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2025
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II populationJ F Seligmann, D Morton, F Elliott, et al.
Nature Communications|November 30, 2023
Volcaniclastic density currents explain widespread and diverse seafloor impacts of the 2022 Hunga Volcano eruptionSarah Seabrook, Kevin Mackay, Sally J Watson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinomaC R Divgi, N H Bander, A M Scott, et al.
Pageof 37